Sanofi (FRA:SNW) Cyclically Adjusted Revenue per Share: €34.57 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SNW Sanofi SA FRA:SNW
88 GF Score
Price €77.19
GF Value €106.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sanofi Cyclically Adjusted Revenue per Share?

Sanofi FRA:SNW +0.57% 88 Cyclically Adjusted Revenue per Share is €34.57 as of Dec. 2025. GuruFocus rates FRA:SNW with a GF Score™ of 88/100 and a GF Value™ of €106.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sanofi's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was €38.117. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €34.57 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Sanofi's average Cyclically Adjusted Revenue Growth Rate was 2.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sanofi was 10.60% per year. The lowest was 1.50% per year. And the median was 3.30% per year.

As of today (2026-07-20), Sanofi's current stock price is € 77.19. Sanofi's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was €34.57. Sanofi's Cyclically Adjusted PS Ratio of today is 2.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanofi was 3.60. The lowest was 2.12. And the median was 2.93.


Sanofi  (FRA:SNW) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sanofi's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=77.19/34.57
=2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanofi was 3.60. The lowest was 2.12. And the median was 2.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sanofi Cyclically Adjusted Revenue per Share Related Terms


Sanofi Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sanofi's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Cyclically Adjusted Revenue per Share Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.29 31.08 32.53 33.51 34.57

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.53 0.00 33.51 0.00 34.57

FRA:SNW vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi's Cyclically Adjusted PS Ratio falls into.


FRA:SNW
88GF Score
Sanofi SA FRA:SNW
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sanofi's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=38.117/120.9000*120.9000
=38.117

Current CPI (Dec. 2025) = 120.9000.

Sanofi Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 26.772 100.650 32.158
201712 28.593 101.850 33.941
201812 28.423 103.470 33.211
201912 29.935 104.980 34.475
202012 29.656 104.960 34.160
202112 31.143 107.850 34.911
202212 32.271 114.160 34.176
202312 33.125 118.390 33.827
202412 35.257 119.950 35.536
202512 38.117 120.900 38.117

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €34.57 mean?
Sanofi (FRA:SNW) has a Cyclically Adjusted Revenue per Share of €34.57 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sanofi and its competitors.
Is Sanofi's Cyclically Adjusted Revenue per Share too high?
Sanofi's current Cyclically Adjusted Revenue per Share is €34.57. Overall, Sanofi has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Sanofi's Cyclically Adjusted Revenue per Share of €34.57 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sanofi and its competitors. Sanofi's current Cyclically Adjusted Revenue per Share is €34.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (FRA:SNW) is currently considered Modestly Undervalued. The stock's GF Value™ is €106.93, compared to a current price of €77.19 — trading 27.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €34.57. Sanofi's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sanofi (FRA:SNW), the current Cyclically Adjusted Revenue per Share is €34.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (FRA:SNW) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €77.19 is trading 27.8% below its estimated GF Value™ of €106.93. GuruFocus considers Sanofi to be Modestly Undervalued.

Key valuation signals for FRA:SNW:

  • Cyclically Adjusted Revenue per Share: €34.57
  • GF Value™: €106.93 vs. price of €77.19 (27.8% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the FRA:SNW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
88GF Score

Get the complete analysis for FRA:SNW

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.19
Price
€106.93
GF Value